These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

569 related articles for article (PubMed ID: 28925296)

  • 1. Vaccine approaches conferring cross-protection against influenza viruses.
    Vemula SV; Sayedahmed EE; Sambhara S; Mittal SK
    Expert Rev Vaccines; 2017 Nov; 16(11):1141-1154. PubMed ID: 28925296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies towards universal pandemic influenza vaccines.
    He F; Leyrer S; Kwang J
    Expert Rev Vaccines; 2016; 15(2):215-25. PubMed ID: 26641724
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vaccination with Vesicular Stomatitis Virus-Vectored Chimeric Hemagglutinins Protects Mice against Divergent Influenza Virus Challenge Strains.
    Ryder AB; Nachbagauer R; Buonocore L; Palese P; Krammer F; Rose JK
    J Virol; 2015 Dec; 90(5):2544-50. PubMed ID: 26676789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards a universal influenza vaccine: different approaches for one goal.
    Sautto GA; Kirchenbaum GA; Ross TM
    Virol J; 2018 Jan; 15(1):17. PubMed ID: 29370862
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospects for antibody-based universal influenza vaccines in the context of widespread pre-existing immunity.
    Wheatley AK; Kent SJ
    Expert Rev Vaccines; 2015; 14(9):1227-39. PubMed ID: 26175180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Progress on adenovirus-vectored universal influenza vaccines.
    Xiang K; Ying G; Yan Z; Shanshan Y; Lei Z; Hongjun L; Maosheng S
    Hum Vaccin Immunother; 2015; 11(5):1209-22. PubMed ID: 25876176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mosaic H5 Hemagglutinin Provides Broad Humoral and Cellular Immune Responses against Influenza Viruses.
    Kamlangdee A; Kingstad-Bakke B; Osorio JE
    J Virol; 2016 Aug; 90(15):6771-6783. PubMed ID: 27194759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Call for a paradigm shift in the design of universal influenza vaccines by harnessing multiple correlates of protection.
    Jang YH; Seong BL
    Expert Opin Drug Discov; 2020 Dec; 15(12):1441-1455. PubMed ID: 32783765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress in the Development of Universal Influenza Vaccines.
    Sun W; Luo T; Liu W; Li J
    Viruses; 2020 Sep; 12(9):. PubMed ID: 32957468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Virus-specific T cells as correlate of (cross-)protective immunity against influenza.
    Altenburg AF; Rimmelzwaan GF; de Vries RD
    Vaccine; 2015 Jan; 33(4):500-6. PubMed ID: 25498210
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-protective immune responses elicited by live attenuated influenza vaccines.
    Jang YH; Seong BL
    Yonsei Med J; 2013 Mar; 54(2):271-82. PubMed ID: 23364956
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Universal influenza vaccines, a dream to be realized soon.
    Zhang H; Wang L; Compans RW; Wang BZ
    Viruses; 2014 Apr; 6(5):1974-91. PubMed ID: 24784572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Adenovirus-Vectored Influenza Vaccine Induces Durable Cross-Protective Hemagglutinin Stalk Antibody Responses in Mice.
    Kim EH; Han GY; Nguyen H
    Viruses; 2017 Aug; 9(8):. PubMed ID: 28825679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Universal influenza vaccines: from viruses to nanoparticles.
    Wang Y; Deng L; Kang SM; Wang BZ
    Expert Rev Vaccines; 2018 Nov; 17(11):967-976. PubMed ID: 30365905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A virus-like particle vaccination strategy expands its tolerance to H3N2 antigenic drift by enhancing neutralizing antibodies against hemagglutinin stalk.
    Yang JR; Cheng CY; Chen CY; Lin CH; Kuo CY; Huang HY; Wu FT; Yang YC; Wu CY; Liu MT; Hsiao PW
    Antiviral Res; 2017 Apr; 140():62-75. PubMed ID: 28093338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Universal Influenza Vaccines: Progress in Achieving Broad Cross-Protection In Vivo.
    Epstein SL
    Am J Epidemiol; 2018 Dec; 187(12):2603-2614. PubMed ID: 30084906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Broadly protective influenza vaccines: design and production platforms.
    Elbahesh H; Saletti G; Gerlach T; Rimmelzwaan GF
    Curr Opin Virol; 2019 Feb; 34():1-9. PubMed ID: 30497050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Universal influenza vaccines: Shifting to better vaccines.
    Berlanda Scorza F; Tsvetnitsky V; Donnelly JJ
    Vaccine; 2016 Jun; 34(26):2926-2933. PubMed ID: 27038130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Universal influenza vaccines, science fiction or soon reality?
    de Vries RD; Altenburg AF; Rimmelzwaan GF
    Expert Rev Vaccines; 2015; 14(10):1299-301. PubMed ID: 26104835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adenovirus vector-based multi-epitope vaccine provides partial protection against H5, H7, and H9 avian influenza viruses.
    Hassan AO; Amen O; Sayedahmed EE; Vemula SV; Amoah S; York I; Gangappa S; Sambhara S; Mittal SK
    PLoS One; 2017; 12(10):e0186244. PubMed ID: 29023601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.